Results 131 to 140 of about 1,869,696 (352)

A Dirichlet-multinomial mixed model for determining differential abundance of mutational signatures

BMC Bioinformatics
Background Mutational processes of diverse origin leave their imprints in the genome during tumour evolution. These imprints are called mutational signatures and they have been characterised for point mutations, structural variants and copy number ...
Lena Morrill Gavarró, Dominique-Laurent Couturier, Florian Markowetz   +2 more
doaj   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus

Nature Communications, 2020
The genomic heterogeneity of clear cell renal cell carcinoma (ccRCC) across populations is poorly understood. Here, the authors analyse a cohort of Chinese ccRCC cases revealing a mutational signature associated with aristolochic acid exposure, and ...
Xiang-Ming Wang, Yang Lu, Yi-Meng Song, Jun Dong, Ruo-Yan Li, Guo-Liang Wang, Xu Wang, Shu-Dong Zhang, Zhou-Huan Dong, Min Lu, Shi-Yu Wang, Li-Yuan Ge, Guang-Da Luo, Run-Zhuo Ma, Steve George Rozen, Fan Bai, Di Wu, Lu-Lin Ma   +17 more
doaj   +1 more source

Predictive genomics: A cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data

, 2014
We discuss a cancer hallmark network framework for modelling genome-sequencing data to predict cancer clonal evolution and associated clinical phenotypes.
Masoudi-Nejad, Ali, Mcgee, Shauna, Milanese, Jean-Sébastien, O'Connor, Maureen, Wang, Edwin, Zaman, Naif   +5 more
core   +1 more source

Colibactin Causes Colorectal Cancer–Associated Mutational Signature [PDF]

Cancer Discovery, 2020
Abstract The pks+ E. coli metabolite colibactin caused a unique mutational signature in intestinal organoids.
openaire   +2 more sources

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source

Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer. [PDF]

, 2018
Triple-negative breast cancers (TNBC) lack estrogen and progesterone receptors and HER2 amplification, and are resistant to therapies that target these receptors.
Boymoushakian, Lari, Chiu, Alec M, Coller, Hilary A, Mitra, Mithun   +3 more
core  

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source

Mutational signature learning with supervised negative binomial non-negative matrix factorization

Bioinform., 2020
Motivation Understanding the underlying mutational processes of cancer patients has been a long-standing goal in the community and promises to provide new insights that could improve cancer diagnoses and treatments. Mutational signatures are summaries of
Xinrui Lyu, Jean Garret, G. Rätsch, K. Lehmann   +3 more
semanticscholar   +1 more source